The stock of Replimune Group Inc (NASDAQ: REPL) has decreased by -3.20 when compared to last closing price of 14.07. Despite this, the company has experienced a -0.95% fall in its stock price over the last five trading sessions. zacks.com reported 2025-01-22 that The FDA accepts and grants priority review to Replimune’s BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
The 36-month beta value for REPL is also noteworthy at 1.31. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for REPL is 61.36M, and at present, short sellers hold a 11.83% of that float. The average trading volume of REPL on January 31, 2025 was 891.91K shares.
REPL’s Market Performance
REPL stock saw an increase of -0.95% in the past week, with a monthly gain of 11.09% and a quarterly increase of 13.03%. The volatility ratio for the week is 6.90%, and the volatility levels for the last 30 days are 8.31% for Replimune Group Inc (REPL). The simple moving average for the past 20 days is 12.09% for REPL’s stock, with a 34.49% simple moving average for the past 200 days.
Analysts’ Opinion of REPL
Many brokerage firms have already submitted their reports for REPL stocks, with ROTH MKM repeating the rating for REPL by listing it as a “Buy.” The predicted price for REPL in the upcoming period, according to ROTH MKM is $17 based on the research report published on August 28, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see REPL reach a price target of $44. The rating they have provided for REPL stocks is “Overweight” according to the report published on April 17th, 2023.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $52 in the report published on November 19th of the previous year.
REPL Trading at 9.84% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.88% of loss for the given period.
Volatility was left at 8.31%, however, over the last 30 days, the volatility rate increased by 6.90%, as shares surge +10.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.47% upper at present.
During the last 5 trading sessions, REPL fell by -0.95%, which changed the moving average for the period of 200-days by +90.76% in comparison to the 20-day moving average, which settled at $12.15. In addition, Replimune Group Inc saw 12.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Patel Sushil, who sale 10,000 shares at the price of $12.42 back on Dec 16 ’24. After this action, Patel Sushil now owns 202,014 shares of Replimune Group Inc, valued at $124,200 using the latest closing price.
Sushil Patel, the Chief Strategy Officer of Replimune Group Inc, proposed sale 15,000 shares at $12.57 during a trade that took place back on Dec 16 ’24, which means that Sushil Patel is holding shares at $188,550 based on the most recent closing price.
Stock Fundamentals for REPL
Current profitability levels for the company are sitting at:
- -57.29 for the present operating margin
- 0.48 for the gross margin
The net margin for Replimune Group Inc stands at -52.7. The total capital return value is set at -0.51. Equity return is now at value -50.32, with -40.17 for asset returns.
Based on Replimune Group Inc (REPL), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.38. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -31.16.
Currently, EBITDA for the company is -230.2 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 244.62. The receivables turnover for the company is 4.86for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.11.
Conclusion
In summary, Replimune Group Inc (REPL) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
